The board of directors of Shanghai Junshi Biosciences Co., Ltd. announced that the company's product Toripalimab Injection (trade name: TUOYI) and Deuremidevir Hydrobromide Tablets (trade name: MINDEWEI) were successfully included in Category B of the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (Year 2023) (the NRDL) upon negotiations. In particular, TUOYI has 3 new indications included, all six approved indications of TUOYI in China are included in the NRDL currently, and TUOYI is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma. The indication of MINDEWEI for adult patients with mild to moderate coronavirus disease 2019 (COVID-19) is officially included in the NRDL for the first time.